A Study of Safety and Effectiveness of NovoThirteen® (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan

NCT02670213 · clinicaltrials.gov ↗

COMPLETED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Congenital Bleeding Disorder
Congenital FXIII Deficiency

Interventions

DRUG: recombinant factor XIII

Sponsor

Novo Nordisk A/S